INS and Insulin resistance: 2012), and there is an unmet need for improved therapy for this disorder. Treatment with RG‐125(AZD4076) is based on its ability to inhibit the activity of miR‐103/107, whose hepatic upregulation causes insulin resistance (Trajkovski et al. 2011). AntagomiR‐based silencing of miR‐103/107 in mice was followed by decreased liver triglyceride content and improved insulin sensitivity. RG‐125 (AZD4076) has therefore the potential to acts as an efficacious insulin sensitizer (RegulusTherapeutics 2015).